Dendrimer

Results: 149



#Item
41Microsoft Word - 140714_FDA agreement for Phase 3 Recurrent BV trial

Microsoft Word - 140714_FDA agreement for Phase 3 Recurrent BV trial

Add to Reading List

Source URL: www.starpharma.com

Language: English - Date: 2014-07-13 20:48:03
424 Nanodevice Technologies – From New Functions of Extreme Substances to Telecommunication Technologies – 4-1 Controlling Intermolecular Interactions using Nano-Structural Molecules OTOMO Akira, YOKOYAMA Shiyoshi, FUR

4 Nanodevice Technologies – From New Functions of Extreme Substances to Telecommunication Technologies – 4-1 Controlling Intermolecular Interactions using Nano-Structural Molecules OTOMO Akira, YOKOYAMA Shiyoshi, FUR

Add to Reading List

Source URL: www.nict.go.jp

Language: English - Date: 2013-11-21 18:52:27
43Starpharma’s docetaxel superior to Taxotere® across multiple cancer types Melbourne, Australia; Thursday 6 December 2012: Starpharma (ASX:SPL; OTCQX:SPHRY) today announced the results of animal trials which show its d

Starpharma’s docetaxel superior to Taxotere® across multiple cancer types Melbourne, Australia; Thursday 6 December 2012: Starpharma (ASX:SPL; OTCQX:SPHRY) today announced the results of animal trials which show its d

Add to Reading List

Source URL: www.starpharma.com

Language: English - Date: 2012-12-05 20:32:48
44Starpharma’s docetaxel demonstrates targeted tumour delivery Melbourne, Australia; 29th October 2012: Starpharma Holdings Ltd (ASX:SPL;OTCQX: SPHRY) today reported significant tumour-targeting results with its propriet

Starpharma’s docetaxel demonstrates targeted tumour delivery Melbourne, Australia; 29th October 2012: Starpharma Holdings Ltd (ASX:SPL;OTCQX: SPHRY) today reported significant tumour-targeting results with its propriet

Add to Reading List

Source URL: www.starpharma.com

Language: English - Date: 2012-10-28 19:02:03
454-3 Development of Molecular-beam Apparatus with Spray-jet Technique YAMADA Toshiki, SUZUKI Hitoshi, SHINOHARA Hidenori, and MASHIKO Shinro We developed a molecular-beam apparatus with a spray-jet technique that produces

4-3 Development of Molecular-beam Apparatus with Spray-jet Technique YAMADA Toshiki, SUZUKI Hitoshi, SHINOHARA Hidenori, and MASHIKO Shinro We developed a molecular-beam apparatus with a spray-jet technique that produces

Add to Reading List

Source URL: www.nict.go.jp

Language: English - Date: 2013-11-21 18:52:59
46Half Year Results Period ended 31 December 2007 Melbourne, Australia; 21 February 2008: Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) today announced its financial results for the six months ending 31 December 2007.

Half Year Results Period ended 31 December 2007 Melbourne, Australia; 21 February 2008: Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) today announced its financial results for the six months ending 31 December 2007.

Add to Reading List

Source URL: www.starpharma.com

Language: English - Date: 2011-06-26 22:21:36
47Starpharma’s Dendrimer-Docetaxel eliminates neutropenia Melbourne Australia; 24 October[removed]Starpharma Holdings Ltd (ASX: SPL; OTCQX: SPHRY) today announced additional positive results for its dendrimer formulation

Starpharma’s Dendrimer-Docetaxel eliminates neutropenia Melbourne Australia; 24 October[removed]Starpharma Holdings Ltd (ASX: SPL; OTCQX: SPHRY) today announced additional positive results for its dendrimer formulation

Add to Reading List

Source URL: www.starpharma.com

Language: English - Date: 2013-10-23 21:11:12
48Starpharma Interim Report and Half-year Financial Results Melbourne, Australia; 24 February 2014: Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) today released its interim report and financial results for the half-ye

Starpharma Interim Report and Half-year Financial Results Melbourne, Australia; 24 February 2014: Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) today released its interim report and financial results for the half-ye

Add to Reading List

Source URL: www.starpharma.com

Language: English - Date: 2014-02-23 21:53:43
49IN THIS ISSUE › Phase 3 clinical trial results for treatment of bacterial vaginosis › Rapid resolution of symptoms; strong patient acceptability for VivaGel®

IN THIS ISSUE › Phase 3 clinical trial results for treatment of bacterial vaginosis › Rapid resolution of symptoms; strong patient acceptability for VivaGel®

Add to Reading List

Source URL: www.starpharma.com

Language: English - Date: 2012-12-18 18:48:48
50Starpharma Annual Report[removed]Starpharma Holdings Limited Baker Building 75 Commercial Road, Melbourne VIC 3004 Australia

Starpharma Annual Report[removed]Starpharma Holdings Limited Baker Building 75 Commercial Road, Melbourne VIC 3004 Australia

Add to Reading List

Source URL: www.starpharma.com

Language: English - Date: 2011-06-26 22:21:33